louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04427813: Sexual Health and Problems During the Covid -19 Infection
Official title: Sexual and Marital Health and Problems During the Covid -19 in the Last Months
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sexual Behavior
Lead sponsor: Aljazeera Hospital
Sponsor class: OTHER
Collaborators: name: Al-Azhar University
First posted: 2020-06-11
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: partners betwen 18-60 years

Brief summary: Covid-19 is an emerging critical highly infectious virus

Detailed description: The covid-19 pandemic is a very harmful crisis that affects all human activities

Eligibility criteria: Inclusion Criteria:

* any partners between 18-60 years

Exclusion Criteria:

* any husband or wife that have organic sexual problems

Primary outcomes:
measure: the number of partners that have unusual behaviour
timeFrame: One month
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Algazeerah
Study officials:
affiliation: Algezeera hospitaland National Research Centre ,Egypt
name: Mahmoud Alalfy, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06180213: Study of Cerebral Glucose Metabolism in Neurodegenerative Diseases and Head Trauma
Official title: Study of Cerebral Glucose Metabolism in Neurodegenerative Diseases and Head Trauma: Retrospective Review of an Large Cohort of FDG PET Data
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neurodegenerative Diseases
Lead sponsor: IRCCS San Raffaele
Sponsor class: OTHER
First posted: 2023-12-22
Enrollment: 1570
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients suffering from various forms of Alzheimer's dementia, Parkinsonism, ALS, motor neuron diseases.

Brief summary: The reason why each specific degenerative disease is characterized by a different FDG PET pattern is still unclear today. There are four main hypotheses proposed to explain this selective vulnerability: 1) Nodal stress, theory according to which the main nodes of specific brain networks undergo wear and tear, 2) trans-neuronal diffusion, theory according to which some toxic agents/proteins or altered propagate along network connections through "Prion-like" mechanisms, 3) trophic failure, in which the interruption of inter-modal connectivity causes the loss of collateral trophic factors, and finally 4) shared vulnerability in which regions also distant from each other are part of a common network which gives a susceptibility uniformly distributed throughout the network.

FDG PET provides in-vivo information on the distribution of brain synaptic dysfunction prior to complete neural death, and represents the main in vivo biomarker of neural dysfunction associated with different clinical conditions characterized by neurodegeneration phenomena. For this reason, FDG PET is considered a fundamental approach to shed light on the causes of selective brain vulnerability in various pathological conditions.


Eligibility criteria: Inclusion Criteria:

* presence of diagnosis of neurodegenerative disease.

Exclusion Criteria:

* patients\< 18 years

Primary outcomes:
measure: FDG PET to measure brain areas of hypo or hyper regional metabolism in patients with neurodegenerative disease.
timeFrame: 4 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04758013: Comparison of Changes of ONSD Between Groups of Laparoscopic Surgery With and Without Epidural Saline Injection
Official title: Comparison of Changes of ONSD Between Groups of Laparoscopic Surgery With and Without Epidural Saline Injection
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Optic Nerve Sheath Diameter
Pneumoperitoneum
Epidural
Keywords: ONSD
pneumoperitoneum
epidural
Lead sponsor: Keimyung University Dongsan Medical Center
Sponsor class: OTHER
First posted: 2021-02-17
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study targets patients undergoing laparoscopic gastric cancer surgery.

The investigators would like to compare two factors that influence intracranial pressure through optic nerve sheath diameter measurement.

First factor is intraperitoneal pressure.

Second factor is epidural pressure.

The investigators divided the patients into three groups.

Group A is patients with laparoscopic gastric surgery who received epidural injection through an thoracic epidural catheter.

Group B is patients with laparoscopic gastric surgery who don't received epidural injection through an thoracic epidural catheter.

Group C is patients with open gastric surgery.


Eligibility criteria: Inclusion Criteria:

* Gastric surgery due to cancer

Exclusion Criteria:

* Coagulopathy
* Infection
* Previous history of thoracic spine surgery
* Ophthalmic diseases
* History of increased Intracranial Pressure

Primary outcomes:
measure: T0 : Optic nerve sheath diameter
timeFrame: 10 minutes after anesthesia induction
measure: T1 : Optic nerve sheath diameter
timeFrame: 10min after entering the laparoscope
measure: T2 : Optic nerve sheath diameter
timeFrame: 1hour after entering the laparoscope
measure: T3 : Optic nerve sheath diameter
timeFrame: 10min after the laparoscopy comes out
Secondary outcomes:
Other outcomes:
Locations:
city: Daegu
country: Korea, Republic of
facility: KeimyungUniversity
Study officials:
affiliation: Keimyung University Dongsan Medical Center
name: JiSeob Kim
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kim JS, Hong JH, Park JH. Comparison of Changes in the Optic Nerve Sheath Diameter Following Thoracic Epidural Normal Saline Injection in Laparoscopic Surgery. Pain Physician. 2022 Jul;25(4):E563-E569.
Clinical trial NCT00310713: Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine
Official title: A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Prevention of Meningococcal Infection
Keywords: Prevention of Meningococcal Meningitis
vaccines
conjugate
immunology
children
antibody persistence
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2006-04-04
Enrollment: 33
Sex: ALL
Minimum age (years): 12
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Persistence of antibodies and kinetics of B cell response in healthy children after vaccination with MCC vaccine


Eligibility criteria: Inclusion Criteria:

* Healthy children

Exclusion Criteria:

* Known hypersensitivity to any vaccine products
* Any immunodeficiency, genetic anomaly or severe acute or chronic illness

Primary outcomes:
measure: Persistence of memory B cells in the blood at least one year after primary immunisation with MenC Vaccine at 2, 3 and 4 months of age, as determined by meningococcal C specific B-cell ELISPot assay or limiting dilution
Secondary outcomes:
measure: Immune Response measured 4 weeks after the booster immunisation.
measure: establish at which day CRM -197 specific B cells are detectable in the blood after booster immunisation, as determined by meningococcal C specific B-cell ELISpot assay or limiting dilution.
Other outcomes:
Locations:
city: Headington
country: United Kingdom
facility: Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road
state: Oxford
Study officials:
affiliation: Novartis Vaccines & Diagnostics
name: Novartis Vaccines - Information Services
role: PRINCIPAL_INVESTIGATOR
References:
citation: Blanchard Rohner G, Snape MD, Kelly DF, John T, Morant A, Yu LM, Borkowski A, Ceddia F, Borrow R, Siegrist CA, Pollard AJ. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol. 2008 Feb 15;180(4):2165-73. doi: 10.4049/jimmunol.180.4.2165.
Clinical trial NCT02548013: Preterm Premature Rupture of Membranes, Outpatient Management vs Inpatient Management
Official title: Is Outpatient Management of PPROM Equivalent to Hospital Management
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Preterm Premature Rupture of Membranes
Lead sponsor: Ain Shams Maternity Hospital
Sponsor class: OTHER
Collaborators: name: Ain Shams University
First posted: 2015-09-14
Enrollment: 560
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study is to compare the maternal and neonatal outcomes in the patients with PPROM who are managed at home versus those managed at hospital, half the patients will be managed at home and the other half will be managed inpatient.

Detailed description: Now the current practice is to manage patients with PPROM at hospital, however it is not known yet whether this practice is better than outpatient management as regard maternal and neonatal outcome.

There is some recent evidence that home management of PPROM is safe for both mother and neonate, home management is also more convenient with less expenses.

Eligibility criteria: Inclusion Criteria:

1. PPROM with gestational age between 27 to 34 weeks
2. Cephalic presentation
3. Clear amniotic fluid
4. Oral temperature \> 38 C
5. Near distance from the hospital (the patient can reach hospital within one hour )
6. Home environment safe and amenable to rest , availability of family support such as a sister or mother who will help the patient at home .
7. Maternal and fetal condition remain stable after hospitalization for 72 hours

Exclusion Criteria:

1. Patient with equivocal diagnosis of rupture of membranes
2. advanced labor
3. intrauterine infection
4. vaginal bleeding or
5. non reassuring fetal heart rate.

Primary outcomes:
measure: rate occurence of Neonatal sepsis
timeFrame: 48 hours after delivery
Secondary outcomes:
measure: rate of occurence of Maternal morbidity
timeFrame: 48 hours after delivery
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams Maternity hospital
state: Abbasya
Study officials:
affiliation: Ain Shams University maternity hospital
name: Maged R Aboseda, professor
role: STUDY_CHAIR
References:
Clinical trial NCT05510713: Blood Purification Therapy With Dual-cannula in Jugular-femoral Venous
Official title: Preliminary Study on the Effect of Blood Purification Therapy With Dual-cannula in Jugular-femoral Venous
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Blood Purification
Dual-cannula
Vena Cava Disconnection
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
First posted: 2022-08-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Acute kidney failure (AKI) is one of the most important causes of morbidity and mortality for critical ill patients. The use of blood purification treatment such as renal replacement therapy (CRRT) and plasma exchange has gradually developed into an effective treatment. However, the efficiency of blood purification may be affected by the recirculation of dual-lumen venous catheter for some special patients including patients with vena cava reflux disorder from massive occupations or ascites. For extreme cases like patients with vena cava disconnection or severe obstruction, the traditional blood purification treatment cannot work effectively. Thus, we used the dual-cannula in jugular-femoral venous blood purification therapy in the following two patients and found that it can improve the perfusion of systemic circulation and the prognosis of patients


Eligibility criteria: Inclusion Criteria:

* 1. patients requiring haemodilution therapy for various reasons (acute renal failure, acute liver failure, etc.)
* 2. presence of superior vena cava and/or inferior vena cava reflux disorders
* 3. age greater than 18 years

Exclusion Criteria:

* 1. Inability to establish suitable vascular access
* 2. Pregnant women
* 3. Not agreeing to active life support treatment
* 4. Severe active bleeding

Primary outcomes:
measure: vasoactive drugs
timeFrame: 144 hours after dual-cannula in jugular-femoral venous
measure: ICU mortality
timeFrame: 28-day ICU mortality
Secondary outcomes:
measure: Cytokine
timeFrame: 24hous after dual-cannula in jugular-femoral venous
Other outcomes:
Locations:
Study officials:
affiliation: Shanghai Zhongshan Hospital
name: Minjie Ju, PHD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01015313: Effects of Intensified Sodium Management in Hemodialysis Patients
Official title: A Multi-center, Randomized, Controlled and Prospective Pilot Study on the Effects of Intensified Sodium Management on Hospitalization in Chronic Hemodialysis Patients.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Renal Failure Chronic Requiring Hemodialysis
Keywords: sodium, hypertension, volume overload
Lead sponsor: Renal Research Institute
Sponsor class: OTHER
First posted: 2009-11-18
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary aim of this study is to investigate whether intensive sodium management by dietary sodium restriction and by preventing positive sodium balance during dialysis can be successfully applied in chronic hemodialysis patients. Secondary aims are to test if sodium restriction has positive effects on the frequency of hospital admissions, blood pressure, fluid overload, quality of life and residual renal function.


Eligibility criteria: Inclusion Criteria:

* Ambulatory, clinically stable maintenance hemodialysis patients on a thrice weekly HD regimen.
* Willing and able to provide written, signed informed consent after the nature of the study has been explained.
* Willing and able to comply with all study procedures.
* Age ≥18 years.

Exclusion Criteria:

* Simultaneous participation in another clinical study except observational trials.
* Any psychological condition which could interfere with the patient's ability to comply with the study protocol.
* Pregnancy.
* Amputation of a limb.
* Pacemaker, implantable pump, artificial joint.
* Expectation that native kidney function will recover.
* Unable to verbally communicate in English or Spanish.
* Scheduled for living donor kidney transplant, change to peritoneal dialysis, home HD or plans to relocate to another center within the next 14 months.
* Life expectancy \< 15 months

Primary outcomes:
measure: feasibility of intensive sodium management
timeFrame: 12 months
Secondary outcomes:
measure: hospitalization
timeFrame: 12 months
Other outcomes:
Locations:
city: New York
country: United States
facility: Irving Place Dialysis Center
state: New York
city: New York
country: United States
facility: Upper Manhattan Dilaysis Center
state: New York
city: New York
country: United States
facility: Yorkville Dialysis Center
state: New York
Study officials:
affiliation: Renal Research Institute
name: Peter Kotanko, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Renal Research Institute
name: Nathan W Levin, MD
role: STUDY_DIRECTOR
References:
citation: McMahon EJ, Campbell KL, Bauer JD, Mudge DW, Kelly JT. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev. 2021 Jun 24;6(6):CD010070. doi: 10.1002/14651858.CD010070.pub3.
Clinical trial NCT01249313: Risk Factor and Outcome of Candidemia
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Candidemia
Keywords: Risk
outcome
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2010-11-29
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patient had candidemia from 2002-2010

Brief summary: Candidemia is the fourth leading cause of hospital-acquired infection in USA. In CMUH, it caused 9% hospital-acquired bloodstream infection in 2008 and 2009. In addition to increased mortality, candidemia also increased hospital stay and cost. There is a trend of increased cases of candidemia in recent years in CMUH. Early empirical and target treatment can reduce mortality and shortened length of hospital stay.

In the past, most prior studies in Taiwan dealt with risk factors for mortality rather than for candidemia and also focused at in vitro susceptibility to antifungal agents. In this study, the investigators hope to analyze the candidemic cases from 2003 to 2009, estimated 1000 cases. There were some rare Candida species. Therefore, the investigators hope to do case study for these diseases to provide the epidemiology of candidemia in CMUH. The result can help clinician in predicting the disease and its outcome. Besides, it also provides the epidemiology of candidemia in mid-Taiwan.


Eligibility criteria: Inclusion Criteria:

* patient had candidemia from 2002-2010

Exclusion Criteria:

* no

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00184613: Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes
Official title: An Open-label, Randomised, In-patient, Cross Over PK/PD Trial Investigating the Pharmackinectic and Pharmacodynamic Profiles Following Continuous Subcutaneous Infusion of Insulin Aspart or Injection of Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes
Diabetes Mellitus, Type 2
Delivery Systems
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2005-09-16
Enrollment: 22
Sex: ALL
Minimum age (years): 30
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This trial is conducted in Europe. The objective of the study is to investigate the effect and safety of continously basal delivered insulin aspart given by a pump versus once daily injection of insulin glargine.


Eligibility criteria: Inclusion Criteria:

* Subjects with type 2 diabetes for more than 2 years
* Subjects currently treated with unchanged insulin glargine dose (10 -100 units) for 2 weeks
* Subjects currently treated with unchanged dose(s) for at least 1 month on one or two Oral Anti-diabetic drugs
* BMI 25 - 40 kg/m2
* HbA1c \< 9.5 %

Exclusion Criteria:

* Known or suspected allergy to trial product(s) or related products
* Previous randomisation in this trial
* Pregnancy, breast-feeding, intention of becoming pregnant or pre-menopausal women judged not to be using adequate contraceptive measures (Only sterilisation, intra uterine devices and contraceptive pills are considered adequate contraceptive methods)
* Mental incapacity, unwillingness or language barriers precluding adequate understanding and co-operation.
* Any other significant illness such as endocrine, cardiac, neurological, malignant or other pancreatic illness judged by Investigator
* Participation in other studies within the last three months

Primary outcomes:
measure: Variation in morning FPG
timeFrame: Collected in hospital on the last 5 days of 7 days hospitalization, and on the morning of discharge
Secondary outcomes:
measure: Variation of plasma endogenous insulin and insulin aspart/glargine collected in hospital on the last 5 days and the morning on discharged
measure: Variation of pre-dinner plasma glucose collected in hospital on the last 3 days
Other outcomes:
Locations:
city: Århus C
country: Denmark
facility: Novo Nordisk Investigational Site
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
Clinical trial NCT05353413: Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy.
Official title: Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Ischemic Optic Neuropathy
Optic Neuritis
Compressive Optic Neuropathy
Traumatic Optic Neuropathy
Toxic Optic Neuropathy
Hereditary Optic Neuropathies
Keywords: optic neuropathies
visual evoked potential
Lead sponsor: Medical University of Bialystok
Sponsor class: OTHER
Collaborators: name: University of Bialystok
First posted: 2022-04-29
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Two groups: volunteers with neuropathies and healthy volunteers
Primary purpose: DIAGNOSTIC

Brief summary: The aim of the project is to create a new, non-invasive and safe protocol for the early diagnosis of various types of optic neuropathies with the use of diffusion magnetic resonance imaging

Detailed description: In this study, it is planned to find twenty volunteers for each of the neuropathies and twenty healthy volunteers. Each volunteer will undergo clinical tests such as visual acuity, color vision, intraocular pressure measurement, assessment of the anterior chamber and fundus using a slit lamp and Volk lens, macular optical coherence tomography examination and examination of the optic nerve disc (OCT), neurological field vision and visual evoked potential (VEP) testing. Each of the volunteers will undergo magnetic resonance imaging. During active scanning, patients will be asked for not blinking or moving their heads by staring at the red dot on the outside of the camera reflected in the coil mirror. The obtained diffusion tensor data will be used for further analysis.

Eligibility criteria: Inclusion Criteria:

Optic neuropathy.

Exclusion Criteria:

common contraindications to MRI (presence of pacemaker, non-MRI-safety or claustrophobia)

Primary outcomes:
measure: sigma parameter
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Wasilkow
country: Poland
facility: Lisowski
Study officials:
References: